Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci

Journal of Clinical Microbiology

Volumn 45, Issue 9, 2007, Pages 2917-2922

  Tenover, Fred C ^a,d   Williams, Portia P ^b   Stocker, Sheila ^a   Thompson, Angela ^a   Clark, Leigh Ann ^a   Limbago, Brandi ^a   Carey, Roberta B ^a   Poppe, Susan M ^c   Shinabarger, Dean ^c   McGowan Jr , John E ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY   (United States)

^c Micromyx   (United States)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID;

ACCURACY; AGAR GEL DIFFUSION; ANALYTICAL EQUIPMENT; ANTIBIOTIC SENSITIVITY; ARTICLE; BROTH MICRODILUTION; DILUTION; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HOMINIS; STAPHYLOCOCCUS SIMULANS; STAPHYLOCOCCUS WARNERI;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DIAGNOSTIC ERRORS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; REPRODUCIBILITY OF RESULTS; STAPHYLOCOCCUS;

STAPHYLOCOCCUS;

EID: 34548684315     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00913-07     Document Type: Article

References (26)

1. Auckland, C., L. Teare, F. Cooke, M. E. Kaufmann, M. Warner, G. Jones, K. Bamford, H. Ayles, and A. P. Johnson. 2002. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J. Antimicrob. Chemother. 50:743-746.
2. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard - seventh edition. Document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial disk susceptibility tests; approved standard - ninth ed. Approved standard M2-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; CLSI approved standard, vol. M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Eliopoulos, G. M. 2003. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin. Infect. Dis. 36:473-481.
6. Fridkin, S. K., C. D. Steward, J. R. Edwards, E. R. Pryor, J. E. McGowan, Jr., L. K. Archibald, R. P. Gaynes, F. C. Tenover, and Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Hospitals. 1999. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Clin. Infect. Dis. 29:245-252.
7. Gemmell, C. G. 2001. Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J. Antimicrob. Chemother. 48:47-52.
8. Gonzales, R. D., P. C. Schreckenberger, M. B. Graham, S. Kelkar, K. DenBesten, and J. P. Quinn. 2001. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357:1179.
9. Jevitt, L. A., A. Smith, P. P. Williams, S. K. Frikin, R. P. Gaynes, J. E. McGowan, Jr., and F. C. Tenover. 2003. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate S. aureus and vancomycin-resistant E. faecium. Microb. Drug Resist. 9:298-306.
10. Johnson, A. P., L. Tysall, M. V. Stockdale, N. Woodford, M. E. Kaufmann, M. Warner, D. M. Livermore, F. Asboth, and F. J. Allerberger. 2002. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis. 21:751-754.
11. Jorgensen, J. H., M. L. McElmeel, and C. W. Trippy. 1997. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimicrob. Agents Chemother. 41:465-467.
12. Livermore, D. M. 2003. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51(Suppl. 2):ii9-ii16.
13. Long, K. S., J. Poehlsgaard, C. Kehrenberg, S. Schwarz, and B. Vester. 2006. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents Chemother. 50:2500-2505.
14. Meka, V. G., and H. S. Gold. 2004. Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39:1010-1015.
15. Meka, V. G., S. K. Pillai, G. Sakoulas, C. Wennersten, L. Venkataraman, P. C. DeGirolami, G. M. Eliopoulos, R. C. Moellering, Jr., and H. S. Gold. 2004. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J. Infect. Dis. 190:311-317.
16. Pillai, S. K., G. Sakoulas, C. Wennersten, G. M. Eliopoulos, R. C. Moellering, Jr., M. J. Ferraro, and H. S. Gold. 2002. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J. Infect. Dis. 186:1603-1607.
17. Prystowsky, J., F. Siddiqui, J. Chosay, D. L. Shinabarger, J. Millichap, L. R. Peterson, and G. A. Noskin. 2001. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 45:2154-2156.
18. Qi, C., X. Zheng, A. Obias, M. H. Scheetz, M. Malczynski, and J. R. Warren. 2006. Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23S rRNA gene in Enterococcus faecium and Enterococcus faecalis. J. Clin. Microbiol. 44:1098-1100.
19. Scheetz, M. H., C. Qi, G. A. Noskin, J. R. Warren, M. J. Postelnick, M. Malczynski, J. Huang, and T. R. Zembower. 2006. The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci. Diagn. Microbiol. Infect. Dis. 56:407-413.
20. Steward, C. D., S. A. Stocker, J. M. Swenson, C. M. O'Hara, J. R. Edwards, R. P. Gaynes, J. E. McGowan, Jr., and F. C. Tenover. 1999. Comparison of agar dilution, disk diffusion, MicroScan, and Vitek antimicrobial susceptibility testing methods to broth microdilution for detection of fluoroquinolone-resistant isolates of the family Enterobacteriaceae. J. Clin. Microbiol. 37:544-547.
21. Steward, C. D., D. Wallace, S. K. Hubert, S. K. Fridkin, R. P. Gaynes, J. E. McGowan, Jr., and F. C. Tenover. 2000. Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of Project ICARE laboratories. Diagn. Microbiol. Infect. Dis. 38:59-67.
22. Tenover, F. C., R. K. Kalsi, P. P. Williams, R. B. Carey, S. Stocker, D. Lonsway, J. K. Rasheed, J. W. Biddle, J. E. McGowan, Jr., and B. Hanna. 2006. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg. Infect. Dis. 12:1209-1213.
23. Tsiodras, S., H. S. Gold, G. Sakoulas, G. M. Eliopoulos, C. Wennersten, L. Venkataraman, R. C. Moellering, and M. J. Ferraro. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207-208.
24. Yagi, B. H., and G. E. Zurenko. 1997. In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria. Anaerobe 3:301-306.
25. Zhu, W., F. C. Tenover, J. Limor, D. Lonsway, D. Prince, W. M. Dunne, Jr., and J. B. Patel. 2007. Use of pyrosequencing to identify point mutations in domain V of 23S rRNA genes of linezolid-resistant Staphylococcus aureus and Staphylococcus epidermidis. Eur. J. Clin. Microbiol. Infect. Dis. 26:161-165.
26. Zurenko, G. E., B. H. Yagi, R. D. Schaadt, J. W. Allison, J. O. Kilburn, S. E. Glickman, D. K. Hutchinson, M. R. Barbachyn, and S. J. Brickner. 1996. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40:839-845.